BioGeneriX AG and Neose Technologies, Inc. Announce Initiation of 2nd Phase I Clinical Trial of GlycoPEG-GCSF; Interim Results From 1st Phase I Trial Show Dose-Dependent Response

MANNHEIM, Germany & HORSHAM, Pa.--(BUSINESS WIRE)--BioGeneriX AG, a member of the ratiopharm Group of companies, and Neose Technologies, Inc. (NasdaqGM:NTEC) today announced that the second Phase I clinical trial of GlycoPEG-GCSF, a long acting granulocyte colony stimulating factor (GCSF), has been initiated. This trial in healthy volunteers will compare a single, subcutaneously administered, fixed dose of GlycoPEG-GCSF versus the approved fixed dose of Amgen’s Neulasta®, the only currently marketed long-acting GCSF. GlycoPEG-GCSF is being developed for the treatment of neutropenia associated with cancer chemotherapy.